Recipient Name Tal Bornstein, CEO, Recipient Title Roei Farhi, CEO, 19, Yad Kharutsim St. Netanya, Sharon area IsraelFEI 3027300316Issued May 4, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3027300316.
Violations2
Issue DateMay 4, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
Naveh Pharma LTD/Bigdam Inc.
Location
Recipient Name Tal Bornstein, CEO, Recipient Title Roei Farhi, CEO, 19, Yad Kharutsim St. Netanya, Sharon area Israel
FEI Number
3027300316
Country
N/A
Issue Date
May 04, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Naveh Pharma LTD/Bigdam Inc. FDA Warning Letter, May 4, 2026
Talk to a Specialist